JP2018520679A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018520679A5 JP2018520679A5 JP2017568207A JP2017568207A JP2018520679A5 JP 2018520679 A5 JP2018520679 A5 JP 2018520679A5 JP 2017568207 A JP2017568207 A JP 2017568207A JP 2017568207 A JP2017568207 A JP 2017568207A JP 2018520679 A5 JP2018520679 A5 JP 2018520679A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- recombinant cell
- intracellular signaling
- protein
- cell according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cell Anatomy 0.000 claims description 44
- 102000004169 proteins and genes Human genes 0.000 claims description 25
- 108090000623 proteins and genes Proteins 0.000 claims description 25
- 108091008042 inhibitory receptors Proteins 0.000 claims description 18
- 102000001702 Intracellular Signaling Peptides and Proteins Human genes 0.000 claims description 17
- 108010068964 Intracellular Signaling Peptides and Proteins Proteins 0.000 claims description 17
- 108091005703 transmembrane proteins Proteins 0.000 claims description 13
- 102000035160 transmembrane proteins Human genes 0.000 claims description 13
- 230000004068 intracellular signaling Effects 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 208000035269 cancer or benign tumor Diseases 0.000 claims description 6
- 210000004698 lymphocyte Anatomy 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 5
- 102000004127 Cytokines Human genes 0.000 claims description 4
- 108090000695 Cytokines Proteins 0.000 claims description 4
- 239000000556 agonist Substances 0.000 claims description 4
- 230000005965 immune activity Effects 0.000 claims description 4
- 230000028993 immune response Effects 0.000 claims description 4
- 230000028327 secretion Effects 0.000 claims description 4
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 claims description 4
- 230000007423 decrease Effects 0.000 claims description 3
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 2
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 2
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 2
- 102000017578 LAG3 Human genes 0.000 claims description 2
- 101150030213 Lag3 gene Proteins 0.000 claims description 2
- 108091000080 Phosphotransferase Proteins 0.000 claims description 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 2
- 230000003213 activating effect Effects 0.000 claims description 2
- 210000001185 bone marrow Anatomy 0.000 claims description 2
- 230000001461 cytolytic effect Effects 0.000 claims description 2
- 230000026731 phosphorylation Effects 0.000 claims description 2
- 238000006366 phosphorylation reaction Methods 0.000 claims description 2
- 102000020233 phosphotransferase Human genes 0.000 claims description 2
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 1
- 238000000034 method Methods 0.000 description 21
- 102000039446 nucleic acids Human genes 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 150000007523 nucleic acids Chemical class 0.000 description 6
- 206010010144 Completed suicide Diseases 0.000 description 5
- 206010021143 Hypoxia Diseases 0.000 description 5
- 230000001146 hypoxic effect Effects 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 102000006601 Thymidine Kinase Human genes 0.000 description 3
- 108020004440 Thymidine kinase Proteins 0.000 description 3
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 230000006052 T cell proliferation Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 229910001882 dioxygen Inorganic materials 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 102100023990 60S ribosomal protein L17 Human genes 0.000 description 1
- 102000004039 Caspase-9 Human genes 0.000 description 1
- 108090000566 Caspase-9 Proteins 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000143 Mouse Proteins Proteins 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562186108P | 2015-06-29 | 2015-06-29 | |
| US62/186,108 | 2015-06-29 | ||
| PCT/US2016/040010 WO2017004150A1 (en) | 2015-06-29 | 2016-06-29 | Immune checkpoint chimeric antigen receptors therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018520679A JP2018520679A (ja) | 2018-08-02 |
| JP2018520679A5 true JP2018520679A5 (enExample) | 2019-08-08 |
Family
ID=57609024
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017568207A Pending JP2018520679A (ja) | 2015-06-29 | 2016-06-29 | 免疫チェックポイントキメラ抗原受容体療法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20180185434A1 (enExample) |
| EP (1) | EP3313892A4 (enExample) |
| JP (1) | JP2018520679A (enExample) |
| KR (1) | KR20180038447A (enExample) |
| CN (1) | CN108137707A (enExample) |
| AU (1) | AU2016285859A1 (enExample) |
| CA (1) | CA2991040A1 (enExample) |
| HK (2) | HK1254820A1 (enExample) |
| IL (1) | IL256643A (enExample) |
| MA (1) | MA42272A (enExample) |
| MX (1) | MX2018000278A (enExample) |
| WO (1) | WO2017004150A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014117121A1 (en) | 2013-01-28 | 2014-07-31 | St. Jude Children's Research Hospital, Inc. | A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease |
| RU2666141C2 (ru) | 2013-09-17 | 2018-09-06 | Оби Фарма, Инк. | Композиции углеводной вакцины для индукции иммунного ответа и их применение при лечении рака |
| KR102211120B1 (ko) | 2014-05-15 | 2021-02-03 | 내셔널 유니버시티 오브 싱가포르 | 변형된 천연 살해 세포 및 그의 용도 |
| BR112017024757A2 (pt) | 2015-05-18 | 2018-11-13 | TCR2 Therapeutics Inc. | composições e métodos para reprogramação de tcr utilizando proteínas de fusão |
| CN115927474A (zh) | 2015-06-19 | 2023-04-07 | 塞巴斯蒂安·科博尔德 | Pd-1-cd28融合蛋白及其在医学中的用途 |
| CA2990694A1 (en) | 2015-07-08 | 2017-01-12 | The Johns Hopkins University | Marrow infiltrating lymphocytes (mils) as a source of t-cells for chimeric antigen receptor (car) therapy |
| US10590169B2 (en) * | 2015-12-09 | 2020-03-17 | Virogin Biotech Canada Ltd | Compositions and methods for inhibiting CD279 interactions |
| WO2017162797A1 (en) * | 2016-03-23 | 2017-09-28 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Fusion proteins of pd-1 and 4-1bb |
| US10980894B2 (en) | 2016-03-29 | 2021-04-20 | Obi Pharma, Inc. | Antibodies, pharmaceutical compositions and methods |
| KR20250048399A (ko) | 2016-04-22 | 2025-04-08 | 오비아이 파머 인코퍼레이티드 | 글로보 계열 항원을 통한 면역 활성화 또는 면역 조정에 의한 암 면역요법 |
| WO2018022933A1 (en) | 2016-07-27 | 2018-02-01 | Obi Pharma, Inc. | Immunogenic/therapeutic glycan compositions and uses thereof |
| EP3491026A4 (en) | 2016-07-29 | 2020-07-29 | OBI Pharma, Inc. | HUMAN ANTIBODIES, PHARMACEUTICAL COMPOSITIONS AND PROCESSES |
| JP2019535731A (ja) | 2016-11-21 | 2019-12-12 | オービーアイ ファーマ，インコーポレイテッド | コンジュゲートさせた生物学的分子、医薬組成物及び方法 |
| AU2017363311A1 (en) | 2016-11-22 | 2019-06-13 | TCR2 Therapeutics Inc. | Compositions and methods for TCR reprogramming using fusion proteins |
| JP2020512284A (ja) * | 2016-12-22 | 2020-04-23 | ウィンドミル セラピューティクス インコーポレイテッド | 免疫系調節組成物および方法 |
| IL269553B2 (en) | 2017-03-27 | 2025-10-01 | Nat Univ Singapore | Truncated NKG2D chimeric receptors and their uses in immunotherapy with natural killer cells |
| WO2018182511A1 (en) | 2017-03-27 | 2018-10-04 | National University Of Singapore | Stimulatory cell lines for ex vivo expansion and activation of natural killer cells |
| US10934336B2 (en) * | 2017-04-13 | 2021-03-02 | The Trustees Of The University Of Pennsylvania | Use of gene editing to generate universal TCR re-directed T cells for adoptive immunotherapy |
| CN111801348A (zh) | 2018-02-09 | 2020-10-20 | 新加坡国立大学 | 活化性嵌合受体及其在自然杀伤细胞免疫疗法中的用途 |
| SG11202008976YA (en) | 2018-04-02 | 2020-10-29 | Nat Univ Singapore | Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells |
| EP3844186A4 (en) | 2018-08-29 | 2022-08-17 | National University of Singapore | METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS |
| CA3120563A1 (en) | 2018-11-26 | 2020-06-04 | Nkarta, Inc. | Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy |
| JP2022513687A (ja) * | 2018-11-30 | 2022-02-09 | ウィンドミル セラピューティクス インコーポレイテッド | キメラ抗原受容体（ｃａｒ）を発現する骨髄浸潤リンパ球（ｍｉｌ）、その製造方法および治療における使用方法 |
| WO2020180882A1 (en) | 2019-03-05 | 2020-09-10 | Nkarta, Inc. | Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy |
| WO2022098985A1 (en) * | 2020-11-05 | 2022-05-12 | Windmil Therapeutics, Inc. | Glioblastoma specific marrow infiltrating lymphocytes and uses thereof |
| JP2023551432A (ja) * | 2020-11-19 | 2023-12-08 | オービーアイ ファーマ，インコーポレイテッド | グロボ系列抗原による免疫モジュレーションによる活動性がん免疫療法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12014500247A1 (en) * | 2011-07-29 | 2014-03-24 | Univ Pennsylvania | Switch costimulatory receptors |
| US9688740B2 (en) * | 2011-10-26 | 2017-06-27 | National Cancer Center | Mutant CTLA4 gene transfected T cell and composition including same for anticancer immunotherapy |
| AU2013204922B2 (en) * | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
| RU2725542C2 (ru) | 2013-05-13 | 2020-07-02 | Селлектис | Способы конструирования высокоактивных т-клеток для иммунотерапии |
| EP3087101B1 (en) | 2013-12-20 | 2024-06-05 | Novartis AG | Regulatable chimeric antigen receptor |
| US20170209492A1 (en) * | 2014-07-31 | 2017-07-27 | Novartis Ag | Subset-optimized chimeric antigen receptor-containing t-cells |
| US9687510B2 (en) * | 2014-09-04 | 2017-06-27 | The Johns Hopkins University | Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions |
| CN115927474A (zh) * | 2015-06-19 | 2023-04-07 | 塞巴斯蒂安·科博尔德 | Pd-1-cd28融合蛋白及其在医学中的用途 |
-
2016
- 2016-06-29 US US15/740,981 patent/US20180185434A1/en not_active Abandoned
- 2016-06-29 HK HK18113910.0A patent/HK1254820A1/zh unknown
- 2016-06-29 EP EP16818647.6A patent/EP3313892A4/en not_active Withdrawn
- 2016-06-29 CN CN201680048831.3A patent/CN108137707A/zh active Pending
- 2016-06-29 KR KR1020187002679A patent/KR20180038447A/ko not_active Withdrawn
- 2016-06-29 HK HK18114773.4A patent/HK1255637A1/zh unknown
- 2016-06-29 MX MX2018000278A patent/MX2018000278A/es unknown
- 2016-06-29 AU AU2016285859A patent/AU2016285859A1/en not_active Abandoned
- 2016-06-29 CA CA2991040A patent/CA2991040A1/en not_active Abandoned
- 2016-06-29 MA MA042272A patent/MA42272A/fr unknown
- 2016-06-29 JP JP2017568207A patent/JP2018520679A/ja active Pending
- 2016-06-29 WO PCT/US2016/040010 patent/WO2017004150A1/en not_active Ceased
-
2017
- 2017-12-28 IL IL256643A patent/IL256643A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7026161B2 (ja) | 免疫調節性融合タンパク質およびその使用 | |
| Zhou et al. | Chimeric antigen receptor T (CAR-T) cells expanded with IL-7/IL-15 mediate superior antitumor effects | |
| Mitra et al. | Interleukin-2 activity can be fine tuned with engineered receptor signaling clamps | |
| van Montfoort et al. | NKG2A blockade potentiates CD8 T cell immunity induced by cancer vaccines | |
| Gargett et al. | GD2-specific CAR T cells undergo potent activation and deletion following antigen encounter but can be protected from activation-induced cell death by PD-1 blockade | |
| IL292650B2 (en) | COSTIMULATORY CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING IL13Ra2 | |
| Sehgal et al. | Programmed death-1 checkpoint blockade in acute myeloid leukemia | |
| Barber et al. | Chimeric NKG2D receptor–expressing T cells as an immunotherapy for multiple myeloma | |
| JP7146397B2 (ja) | 改変γδＴ細胞 | |
| JP2020512284A5 (enExample) | ||
| JP2016520074A5 (enExample) | ||
| JP2017513478A5 (enExample) | ||
| JP2017535292A5 (enExample) | ||
| JP2018029594A5 (enExample) | ||
| JP2021520853A5 (enExample) | ||
| JP2018508219A5 (enExample) | ||
| IL259120A (en) | Her2-targeted antigen chimeric receptors2 | |
| JP2018522592A5 (enExample) | ||
| FI3909972T3 (fi) | Pd1-cd28-fuusioproteiineja ja niiden käyttö lääkkeessä | |
| Tang et al. | CD137 co-stimulation improves the antitumor effect of LMP1-specific chimeric antigen receptor T cells in vitro and in vivo | |
| JP2016534717A5 (enExample) | ||
| JP2019518460A5 (enExample) | ||
| JP2017537627A5 (enExample) | ||
| Merker et al. | Generation and characterization of ErbB2-CAR-engineered cytokine-induced killer cells for the treatment of high-risk soft tissue sarcoma in children | |
| CN118421557A (zh) | 选择性扩增γδT细胞群的方法及其组合物 |